Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease entities : Athira pharma, inc. save search
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
Published: 2024-04-11 (Crawled : 11:00) - globenewswire.com
ATHA | $2.07 -1.9% -1.93% 200K
|
Health Technology
|
| O: 4.9%
H: 6.03%
C: 3.11%
fosgonimeton pharma disease alzheimer’s publication treatment preclinical
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
Published: 2024-01-03 (Crawled : 12:00) - globenewswire.com
ATHA | $2.07 -1.9% -1.93% 200K
|
Health Technology
|
| O: -1.73%
H: 12.32%
C: 6.69%
fosgonimeton pharma disease alzheimer’s lift-ad trial
Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
Published: 2023-12-12 (Crawled : 12:00) - globenewswire.com
ATHA | $2.07 -1.9% -1.93% 200K
|
Health Technology
|
| O: -2.93%
H: 10.55%
C: 6.53%
fosgonimeton pharma disease parkinson's treatment dementia trial results
Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MND
Published: 2023-11-28 (Crawled : 12:00) - globenewswire.com
ATHA | $2.07 -1.9% -1.93% 200K
|
Health Technology
|
| O: -1.96%
H: 0.07%
C: -4.0%
pharma disease symposium presentation international
Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton’s Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer’s Disease
Published: 2023-11-15 (Crawled : 13:00) - globenewswire.com
ATHA | $2.07 -1.9% -1.93% 200K
|
Health Technology
|
| O: 1.97%
H: 6.77%
C: 2.58%
pharma disease alzheimer’s preclinical in vitro
Athira Pharma Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimer’s Disease
Published: 2023-07-17 (Crawled : 11:00) - globenewswire.com
ATHA | $2.07 -1.9% -1.93% 200K
|
Health Technology
|
| O: 2.28%
H: 0.0%
C: -3.5%
pharma disease alzheimer’s biomarkers
Athira Pharma Announces Publication in Journal of Alzheimer’s Disease Highlighting Need for Novel Alzheimer’s Disease Treatment Approaches and Potential of Enhancing HGF/MET Pathway
Published: 2023-02-01 (Crawled : 12:20) - globenewswire.com
ATHA | $2.07 -1.9% -1.93% 200K
|
Health Technology
|
| O: -0.25%
H: 9.43%
C: 4.71%
treatment pharma disease alzheimer’s potential publication hgf/met pathway fosgonimeton
Athira Pharma Highlights Therapeutic Potential of Fosgonimeton in Presentation of Additional Biomarker Data in Mild-to-Moderate Alzheimer’s Disease Patients from ACT-AD Phase 2 Study at CTAD Conference
Published: 2022-11-29 (Crawled : 19:00) - biospace.com/
ATHA | $2.07 -1.9% -1.93% 200K
|
Health Technology
|
| O: -0.35%
H: 3.53%
C: 1.41%
pharma conference disease biomarker alzheimer’s presentation potential study fosgonimeton
Athira Pharma to Present Additional Biomarker Data from ACT-AD Phase 2 Study of Fosgonimeton at the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Published: 2022-11-21 (Crawled : 13:20) - globenewswire.com
ATHA | $2.07 -1.9% -1.93% 200K
|
Health Technology
|
| O: -0.31%
H: 1.56%
C: -0.31%
pharma trials conference disease biomarker alzheimer’s study fosgonimeton phase 2
Athira Pharma to Present Additional Biomarker Data from ACT-AD Phase 2 Study of Fosgonimeton at the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) ConferenceFosgonimeton demonstrates improvement on diverse biomarkers of neurodegeneration
Published: 2022-11-21 (Crawled : 13:00) - biospace.com/
ATHA | $2.07 -1.9% -1.93% 200K
|
Health Technology
|
| O: -0.31%
H: 1.56%
C: -0.31%
pharma trials disease biomarker alzheimer’s biomarkers study fosgonimeton
Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
Published: 2022-06-22 (Crawled : 12:00) - biospace.com/
ATHA | $2.07 -1.9% -1.93% 200K
|
Health Technology
|
| O: -69.76%
H: 17.42%
C: 7.95%
pharma disease topline alzheimer’s results act-ad phase 2 ath-1017 alzheimer's fosgonimeton phase 2
Athira Pharma Extends Ongoing Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for Mild to Moderate Alzheimer’s Disease
Published: 2022-05-09 (Crawled : 12:20) - biospace.com/
ATHA | $2.07 -1.9% -1.93% 200K
|
Health Technology
|
| O: -10.47%
H: 3.1%
C: -2.0%
ath-1017 ongoing pharma trials label disease alzheimer’s alzheimer's fosgonimeton
Athira Pharma Presents Study Overview and Baseline Data from ACT-AD Phase 2 Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease at the 2022 AD/PD™ Congress
Published: 2022-03-20 (Crawled : 12:20) - globenewswire.com
ATHA | $2.07 -1.9% -1.93% 200K
|
Health Technology
| Email alert
Add to watchlist
alzheimer phase 2 trial disease alzheimer’s alzheimer's disease alzheimer's act-ad phase 2 fosgonimeton
Athira Pharma to Present Overview and Update from ACT-AD Phase 2 Trial of Fosgonimeton (ATH-1017) in Mild-to-Moderate Alzheimer’s Disease at AD/PD™ 2022 Congress
Published: 2022-03-14 (Crawled : 14:30) - biospace.com/
ATHA | $2.07 -1.9% -1.93% 200K
|
Health Technology
|
| O: -1.35%
H: 3.46%
C: 0.0%
ath-1017 alzheimer phase 2 trial disease alzheimer’s alzheimer's disease alzheimer's act-ad phase 2 fosgonimeton
Athira Pharma Announces Publication of Phase 1 Results for Fosgonimeton (ATH-1017) in The Journal of Alzheimer's Disease
Published: 2022-02-22 (Crawled : 20:00) - biospace.com/
ATHA | $2.07 -1.9% -1.93% 200K
|
Health Technology
|
| O: -1.18%
H: 3.04%
C: 0.54%
ath-1017 alzheimer disease phase 1 phase 2 alzheimer’s alzheimer's disease alzheimer's fosgonimeton
Athira Pharma Announces Initiation of Patient Dosing in SHAPE, a Phase 2 Clinical Trial of ATH-1017 for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
Published: 2022-01-25 (Crawled : 13:30) - biospace.com/
ATHA | $2.07 -1.9% -1.93% 200K
|
Health Technology
|
| O: -10.1%
H: 13.42%
C: 9.61%
ath-1017 treatment phase 2 dementia parkinson trial disease
Athira Pharma Presents Overview and Update from ACT-AD and LIFT-AD Trials of ATH-1017 in mild-to-moderate Alzheimer’s Disease at CTAD Conference
Published: 2021-11-10 (Crawled : 17:00) - globenewswire.com
ATHA | $2.07 -1.9% -1.93% 200K
|
Health Technology
|
| O: -0.65%
H: 2.92%
C: -3.51%
disease alzheimer ath-1017 trials trial conference alzheimer’s alzheimer's disease alzheimer's
Athira Pharma Announces Completion of Enrollment in Phase 2 ACT-AD Trial Evaluating ATH-1017 for Mild-to-Moderate Alzheimer’s Disease
Published: 2021-10-22 (Crawled : 12:00) - athira.com
ATHA | $2.07 -1.9% -1.93% 200K
|
Health Technology
|
| O: 9.45%
H: 9.46%
C: 1.61%
disease alzheimer phase 2 ath-1017 trial enroll alzheimer’s alzheimer's disease alzheimer's
Athira Pharma to Present Updates from Phase 2/3 Trials of ATH-1017 at the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Published: 2021-09-29 (Crawled : 11:00) - athira.com
ATHA | $2.07 -1.9% -1.93% 200K
|
Health Technology
|
| O: 0.75%
H: 1.17%
C: -0.75%
disease alzheimer phase 2 ath-1017 clinical trials phase 2/3 trials trial conference alzheimer’s alzheimer's disease alzheimer's
Athira Pharma to Present on ERP P300 as a Direct, Functional, Non-Invasive Biomarker at the Annual Biomarkers for Alzheimer’s Disease Summit
Published: 2021-08-23 (Crawled : 12:00) - globenewswire.com
ATHA | $2.07 -1.9% -1.93% 200K
|
Health Technology
|
| O: 0.94%
H: 6.01%
C: 5.7%
disease alzheimer ath-1017 alzheimer’s alzheimer's disease alzheimer's biomarkers
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.